DCVax®-L (Northwest Biotherapeutics GmbH) is a therapeutic agent based on endogenous immune cells that will be used for treating Glioblastoma Multiforme after standard therapy. The treatment is based on immune cells of the peripheral blood which are differentiated in-vitro to specific antigen-presenting cells, dendritic cells (DCs). The immature DCs are subsequently brought into contact with a tumour lysate, and thereby "trained" to recognize tumour cells. The maturated DCs are injected into the patient and can then trigger an immune response against remaining tumour cells. As part of a clinical trial (Phase III) to test the efficacy of DCVax®-L, cells from patients' peripheral blood (peripheral blood mononuclear cells; PBMCs) are isolated, quality controlled and cryopreserved for long-term storage. The aim of the project is to develop suitable diagnostic assays which can demonstrate a functional immune response in patients after treatment with DCVax®-L to support clinical data.